Orthotopic xenograft animal model from human glioblastoma multiforme (GBM) cell lines often do not recapitulate an extremely important aspect of invasive growth and epidermal growth factor receptor (EGFR) gene overexpression of human GBM. We developed an orthotopic xenograft model by solid transplantation of human GBM into the brain of nude mouse. The orthotopic xenografts sharing the same histopathological features with their original human GBMs were highly invasive and retained the overexpression of EGFR gene. The murine orthotopic GBM models constitute a valuable in vivo system for preclinical studies to test novel therapies for human GBM.
INTRODUCTION

Gliomas are the most common forms of primary human brain tumors, and they are often classified into four clinical grades. The most aggressive tumors, grade 4 tumors, also known as glioblastoma multiforme (GBM), are associated with high mortality and morbidity. Survival of patients affected by GBM has remained virtually unchanged during the last decades (i.e., 6-12 months postdiagnosis) despite advances in surgery, radiation, and chemotherapy (1-3). This paradox is notably explained by the impossibility of studying in vivo at the cellular and molecular level, the actions of the multiple possible modalities of treatment on human GBM (4). For these reasons, the development of clinically relevant models for studying GBM is essential for increasing our understanding of their tumorigenesis, biology, as well as for testing novel therapeutic approaches for their improved treatment.
Ideal GBM model should recapitulate key features of the human disease, be accurate, be orthotopic, be reproducible, resemble progression kinetics, and retain the important gene alteration, EGFR gene overexpression or amplification (5) (6) (7) . (8) . In vivo human glioma models developed by subcutaneous (heterotopic) or intracranial (orthotopic) implantation of glioma cell lines in rodents are widely used to test novel therapies for GBM (1, (9) (10) (11) . The advantages of these glioma models are their highly efficient glioma genesis, reproducible growth rates, and an accurate knowledge of the location of the tumor (3) (6, (15) (16) (17) 
Although rodent glioma models have been used in preclinical glioma research for over 30 years, their use remains controversial and these models have been criticized for not
. However, the heterotopic xenografts are not truly representative of the biological characteristics of their original patient GBM, such as invasive growth (4). In addition, in the orthotopic setting, established human GBM cell lines generally also fail to demonstrate the diffusely infiltrative pattern of growth that is typical of human GBM (6); instead, human GBM cell lines tend to form solid masses at the site of injection, which compress rather than invade the surrounding brain parenchyma (12-14). Another major disadvantage of the orthotopic models using xenografted human GBM cell lines in rodents is that genetic alterations present in the original tumor are not often maintained, especially the overexpression or amplification of the EGFR gene that is present in approximately 40%-50% of human GBM is typically not preserved in GBM cell lines and xenografts derived thereof
. Consequently, the heterotopic or orthotopic models from human GBM cell lines do not recapitulate an extremely important aspect of tumor invasion and EGFR gene overexpression, which has somewhat limited its application in clinically relevant researches.
Alternative methods for establishing orthotopic GBM xenograft models have been more successful at maintaining the invasive features of these tumors, such as the direct transplantation of patient surgical material into the brains of nude mice and transplantation of patient surgical material subcutaneously (sc) in nude mice followed by dissociation and orthotopic reinjection of these xenotransplants (18, 19) . Furthermore, the problem of EGFR overexpression loss has previously been overcome by direct implantation of tumor specimens into the flanks of nude mice (19, 20 (Figure 4) . (Figure 1 
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Clinical information
RESULTS
Histopathology of flank xenografts
Neuroimaging
On each occasion, the postgadolinium T1-weighted sequences of the mice brain revealed typical intense contrast enhancement in the right hemisphere of 10 mice per intracranial xenograft line. The contrast-enhanced zones corresponded to the solid tumor component, and edema zone surrounding solid tumor sometime could be detected
The intracranial xenografts shared the similar MRI features with its corresponding human tumors (Figure 1). However, no enhancing masses were observed in the brains of mice in the sham surgical controls (data not shown).
Histopathology of intracranial xenografts In HE-stained sections, features common to the intracranial GBMs in 4 different xenograft lines included high cellular density with frequent nuclear crowding, poorly differentiated pleomorphic cells, some multinucleated cells, and frequent mitoses. Compared with the human surgical material
), the mouse-grown intracranial tumors contained the same morphological cell types, but there was a tendency for the tumor cell composition to appear somewhat more homogeneous (Figure 4). No significant difference in the numbers of necrotic foci was observed between the 4 xenograft lines (Table 2), and the necrotic foci were often surrounded by pseudo-palisading of tumor cells. The presence of microvascular/endothelial proliferation (i.e., multilayered, mitotically active hyperplasic endothelial cells, smooth muscle cells, and pericytes) is a histopathological hallmark of human GBM (24, 25), but endothelial proliferation with multilayering of endothelial cells was not observed in any intracranial xenografts. In sections stained with the monoclonal antibody to mouse CD34 antigen, the microvessels of intracranial xenografts appeared to consist of a continuous single layer of endothelial cells (Figure 4). No significant difference in the numbers of vascularization was observed between the 4 xenograft lines (Table 2). Glomeruloid body-like vasculature formation that occurred in corresponding human GBM was never observed. Vascularization observed in the intracranial xenografts was phenotypically distinct from the human GBM. High invasive growth pattern was a striking feature of the intracerebral xenografts (Figure 5). All xenografts appeared to be composed of two components: solid tumor tissue and invasive tumor cells. The invasive tumor cells, isolated or  D. Yi et al.
. MRI and histopathologic features of intracranial xenografts. The 4 different intracranial xenografts generated from 4 corresponding flank GBM xenograft lines. MRI reveals irregularly and nonhomogeneously enhancing mass (black arrow) in contrast-enhanced T1-weighted imaging, which shared the similar MRI features with its corresponding human tumors. In HE-stained sections, the intracranial xenografts show mitotically active, high cellular density, poorly differentiated pleomorphic cells, necrotic foci, and some multinucleated cells, as well as mild or profuse microvessels (black arrow). Microvessels appear to consist of a continuous single layer of endothelial cells in CD34 immunostaining (black arrow), but endothelial proliferation is not observed compared with human tumors.
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involved the placement of a small tumor fragment into the mouse brain, no intratissular artificial diffusion of the malignant cells can appear, as can occur during intracerebral injections of cell suspensions (26, 27). The migration of tumor cells in the normal host cerebral tissue is easy to identify by using immunostaining techniques or HE staining. Pleomorphic cells with abnormal cytoplasmic and nuclear morphology infiltrating the nonneoplastic brain parenchyma showed EGFR-positive expression (buffy), and they had strongly acidophilic cytoplasm, high nucleus to cytoplasm ratio, and nuclear and cytoplasmic abnormal morphology, indicating that the pleomorphic cells were tumor cells (Figure 5
)
Immunohistochemical analysis of EGFR expression in intracranial xenografts
Immunoreactivity for EGFR protein was noted in all intracranial xenografts. Positive rates of EGFR expression were 69.8% ± 2.9%, 68.4% ± 2.6%, 68.5% ± 3.5%, and 67.4% ± (12) (13) (14) 28) and cannot maintain the overexpression of the key EGFR gene that can promote glioma cell invasion (15-17, 29, 30) .
1.2% in the 4 different intracranial xenografts, respectively, and of which no significant difference in the precentages of EGFR protein expression was observed between each line (Table 2). However, EGFR overexpression features of human
materials (Figure 2), the mouse-grown intracranial tumors retained the biological features of EGFR overexpression.
EGFR transcription and expression
High EGFR transcription level was found in the original patient's GBM tumor and was maintained in all subsequent xenograft lines (flank and cranial) by RT-PCR, and overexpressed EGFR protein was also found in all aforementioned GBM xenografts and its human GBMs by immunoblotting (Figure 7). Here, our RT-PCR and westernblot analysis demonstrated the presence of EGFR gene overexpression in all GBM xenografts compared with its original tumors, suggesting that the intracranial or flank xenograft models can retain the genetic property of EGFR
Figure 7. EGFR transcription and expression in xenografts and its original tumors. Compared with human tumors, the overexpressed EGFR gene is retained in the GBM xenografts of 4 different lines by RT-PCR and western blot analysis. No template for RT-PCR is as negative control. Brain tissues from human specimens of surgical decompression without EGFR expression are as normal control.
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Orthotopic Mouse Model for Glioma  overexpression in clinical GBM by orthotopic or heterotopic retransplantation of human GBM solid tissues.
DISCUSSION
This lack of invasiveness and EGFR overexpression may limit the clinical relevance of studies assessing the efficacy of novel therapies aimed at EGFR and invasion when tested against the intracranial xenografts established from GBM cell lines.
Intracranial GBM xenografts established directly from patient surgical specimens that were maintained as sc xenografts through serial passaging in immune-deficient mice have been previously described (20) . This approach to establish GBM xenograft is the only means that has been shown to preserve tumor EGFR overexpression status and invasive growth pattern when compared with the established cell lines (18, 20, 31 (37, 38) . Nevertheless, these models were widely applied and proved useful when assessing GBM angiogenesis and antiangiogenic therapeutic approaches (6, 39) 
